Genomic Profiling of HER2‐Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2‐Positive Advanced Gastric Cancer Treated with Trastuzumab

BACKGROUND. HER2‐positive gastric cancer (GC) affects 7%–34% of patients with GC. Trastuzumab‐based first‐line treatment has become the standard of care for HER2‐positive advanced gastric cancer (AGC). However, there are no clinically validated biomarkers for resistance to HER2‐targeted therapies. U...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Díaz‐Serrano, Asunción, Angulo, Barbara, Dominguez, Carolina, Pazo‐Cid, Roberto, Salud, Antonieta, Jiménez‐Fonseca, Paula, Leon, Ana, Galan, Maria Carmen, Alsina, Maria, Rivera, Fernando, Plaza, J. Carlos, Paz‐Ares, Luis, Lopez‐Rios, Fernando, Gómez‐Martín, Carlos
Format: Artigo
Sprache:Inglês
Veröffentlicht: AlphaMed Press 2018
Schlagworte:
Gastrointestinal Cancer
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6192610/
https://ncbi.nlm.nih.gov/pubmed/29700210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0379
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge